Diabetes Discourse

Guest: John W. Ostrominski, MD, MPH Prediabetes may signal more than the future development of diabetes; it can also provide an opportunity to identify and address cardiovascular risk earlier. Here to recap his presentation at the 2026 European Association for the Study of Diabetes Annual Meeting is Dr. John Ostrominski, preventive cardiologist and obesity medicine specialist at Brigham and Women'...

Guest: Edward Phelps, PhD Despite advances in type 1 diabetes (T1D) research, key questions remain about disease progression, immune mechanisms, and the optimal timing of intervention. Here to explore how immunology and islet research could help address these knowledge gaps is Dr. Edward Phelps. He’s an Associate Professor in the J. Crayton Pruitt Family Department of Biomedical Engineering at the...

Guest: Vira Kravets, PhD Cellular interactions within pancreatic islets may provide important insights into the early stages and pathogenesis of type 1 diabetes (T1D). Tune in to hear Dr. Vira Kravets share research she presented at the 2026 European Association for the Study of Diabetes Annual Meeting, which focused on how alpha-beta cell proximity influences GLP-1R-mediated communication as well...

Guest: Edward Phelps, PhD Residual beta cells may persist after a type 1 diabetes (T1D) diagnosis, but how well do they continue to function? Tune in to hear Dr. Edward Phelps discuss research he presented at the 2026 European Association for the Study of Diabetes Annual Meeting that examined glucose-stimulated calcium responses in living pancreatic tissue from donors with recent-onset T1D. He exp...

Guest: Laura Chiavaroli, PhD How might diet and exercise influence metabolic outcomes among patients taking GLP-1 medicines? To find out, we recently spoke with Dr. Laura Chiavaroli, who discussed this topic at the 2026 European Association for the Study of Diabetes Annual Meeting. She shares emerging evidence on combining lifestyle interventions with GLP-1 therapy and highlights where gaps in res...

Guest: Scott D. Isaacs, MD FACP, FACE For patients with type 2 diabetes, the latest American Association of Clinical Endocrinology (AACE) guidance supports tailoring hypertension treatment to individual risk profiles. Dr. Scott Isaacs joins us to review updated blood pressure targets, first-line therapies, and management considerations for patients at increased risk. He's the Immediate Past Presid...

Guest: Carel le Roux, MBChB, MSC, FRCP, FRCPath, PhD New findings from the SYNCHRONIZE-1 trial reveal that survodutide's impact extends beyond weight reduction, with a demonstrated decrease in liver fat and meaningful improvements across multiple markers of metabolic health in patients without type 2 diabetes. Dr. Carel le Roux joins us to share the efficacy and safety data and explore what these...

Guest: John W. Ostrominski, MD, MPH Despite advances in glycemic management, blood pressure control, lipid lowering, and disease-modifying therapies, patients with chronic kidney disease (CKD) and type 2 diabetes continue to face substantial residual cardiovascular risk. In this program, Dr. John Ostrominski reviews emerging evidence linking low-grade systemic inflammation to adverse cardiovascula...

Guest: Kimberly Narain, MD, MPH, PhD Cost-related medication nonadherence remains a significant but often hidden barrier to effective diabetes care, with out-of-pocket costs preventing patients from accessing essential therapies. Dr. Kimberly Narain joins us to explain why clinicians should look beyond insurance status alone and consider affordability challenges when developing strategies to impro...

Host: Steve Jackson, PharmD Guest: Souptik Barua, PhD Guest: Emily Johnston, MPH, PhD Can older adults successfully engage with telehealth, wearable technology, and digital health tools to prevent type 2 diabetes? In this conversation with Dr. Steve Jackson, Dr. Emily Johnston and Dr. Souptik Barua discuss emerging insights on how these strategies could improve accessibility and engagement in a hi...

Guest: Javier Morales, MD, FACP, FACE From proactive screening to once-weekly insulin, the treatment landscape for type 1 diabetes is evolving rapidly. Join Dr. Javier Morales to hear about current and emerging care strategies in these patients, a topic he also discussed at the 2026 American Diabetes Association Scientific Sessions. Dr. Morales is an Associate Clinical Professor of Medicine at the...

Guest: Javier Morales, MD, FACP, FACE For patients with obesity and type 2 diabetes (T2D), emerging incretin-based therapies that target multiple metabolic pathways are producing meaningful weight-loss outcomes. To learn more about these care strategies, tune in as Dr. Javier Morales shares key updates from the 2026 American Diabetes Association Scientific Sessions. Dr. Morales is an Associate Cli...

Host: Mara Fiorio, DCN, RD, LD, BC-ADM, CDCES Guest: Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES, FADCES, FCCP Guest: Richard E. Pratley, MD Learn how to optimize guideline-concordant care for patients with type 2 diabetes with this on-demand webcast—featuring the latest data on weekly insulin therapies and expert-informed strategies to support the future integration of these emerging agents in you...

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Ian de Boer, MD Since up to 40 percent of patients with diabetes develop diabetic kidney disease, it’s essential to know how to proactively diagnose and treat them using the latest therapeutic advances and strategies. Tune in to hear Dr. Mary Katherine Cheeley discuss diabetes management in patients with chronic kidney disease with Dr. I...

Guest: Elena Toschi, MD Approximately over the last decade, lifespans in the general population have increased, along with a rise in the prevalence of type 1 diabetes in older adult patients. Since each patient has a unique disease, the clinician should personalize and devise the best approach to diabetes management and glycemic targets, as well as manage comorbidities and complications. To learn...

Host: John Buse, MD, PhD Guest: Kim Boggess, MD The most common forms of diabetes encountered in pregnant patients include gestational diabetes and preexisting type 2 diabetes. So how does adding metformin to insulin treatment help these patients? Join Dr. John Buse as he talks about the MOMPOD Trial with lead author, Dr. Kim Boggess, Professor of Maternal Fetal Medicine at the University of North...

Guest: R. Paul Wadwa, M.D. Since young kids have a different activity level and diet than older kids or adult patients, controlling type 1 diabetes in younger patients can be more challenging, and there tends to be more variability in their blood sugars. However, a recent study identified that hybrid closed-loop technology could help give children with type 1 diabetes the best outcomes and quality...

Host: Carol Wysham Guest: A. Michael Lincoff, MD Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but...

Host: John Buse, MD, PhD Guest: Louis J. Aronne, MD, FTOS In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive furthe...

Host: John Buse, MD, PhD Guest: Mary de Groot, PhD The prevalence of diabetes-related stigma is alarmingly high. In fact, four in five adults have reported experiencing some form of diabetes stigma at some point in their lives. To learn how we as healthcare providers can help reduce this burden for our patients with diabetes, Dr. John Buse speaks with Dr. Mary de Groot, Professor of Medicine and t...

Host: Stuart Weinzimer, MD The artificial pancreas represents the integration of two separate devices: a continuous glucose monitor and an insulin pump. Learn more about this technology and how it can help improve diabetic patients’ quality of life with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

Host: Stuart Weinzimer, MD From continuous glocuose monitors to insulin pumps, there have been immense technological advancements for patients with type 1 diabetes. Learn more about how these two tools can be used to treat pediatric patients with type 1 diabetes with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

Host: John Buse, MD, PhD Guest: Michael Fang, PhD According to a recent study published in the Annals of Internal Medicine , the median age of patients with type 1 diabetes is 24. However, type 1 diabetes that develops in adulthood is often mistakenly identified as type 2 diabetes, resulting in improper treatment. Joining Dr. John Buse to review this study’s key findings and how we can determine i...

Host: John Buse, MD, PhD Guest: Maria Jose Redondo, MD, PhD, MPH A recent paper focused on a variety of topics associated with type 1 diabetes, including its heterogenenity, endotypes, slowly progressive insulin-dependent diabetes, and the term type 1.5 diabetes. Dive into these topics with Dr. John Buse and Dr. Maria Redondo, Professor of Pediatrics in the Division of Pediatric Diabetes and Endoc...

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: David Selzer, MD New research suggests that a GLP-1 receptor agonist medication, semaglutide, which has been approved for type 2 diabetes and obesity, could also be used to treat type 1 diabetes in patients. So what are the risks for patients who have type 1 diabetes and who are obese? Joining Dr. Mary Katherine Cheeley to discuss this i...